The pharmacogenetics and pharmacogenomics of asthma therapy

Pharmacogenomics Journal

Volumn 11, Issue 6, 2011, Pages 383-392

  Tse, S M ^a   Tantisira, K ^a   Weiss, S T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

asthma; pharmacogenetics; treatment response

Indexed keywords

ATRELEUTON; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; METHACHOLINE; MONTELUKAST; PLACEBO; PRANLUKAST; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; ZAFIRLUKAST; ZILEUTON;

ADRB2 GENE; ADVERSE OUTCOME; ALOX5 GENE; ARG1 GENE; ASTHMA; BRONCHOSPASM; CALCIUM CELL LEVEL; CLCA1 GENE; CLINICAL FEATURE; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; CRHR1 GENE; DEATH; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG SAFETY; DUSP1 GENE; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ETHNIC DIFFERENCE; FCER2 GENE; FORCED EXPIRATORY VOLUME; GENE; GENE CONTROL; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; LONG TERM CARE; LUNG FUNCTION; MAINTENANCE THERAPY; MONOTHERAPY; MRP1 GENE; NONHUMAN; PEAK EXPIRATORY FLOW; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY FAILURE; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STIP1 GENE; TBX21 GENE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; PHARMACOGENETICS;

EID: 81755165915     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.46     Document Type: Review

References (85)

1. Akinbami LJ, Moorman JE, Liu X. Asthma Prevalence, Health Care Use, and Mortality: United States, 2005-2009. Natl Health Stat Report 2011; 32: 1-14.
2. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 2011; 127: 145-152.
3. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56: 1054-1070. (Pubitemid 32417168)
4. Thomsen SF, van der Sluis S, Kyvik KO, Skytthe A, Backer V. Estimates of asthma heritability in a large twin sample. Clin Exp Allergy 2010; 40: 1054-1061.
5. Brand PL, Duiverman EJ, Waalkens HJ, van Essen-Zandvliet EE, Kerrebijn KF. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax 1999; 54: 103-107. (Pubitemid 29101351)
6. Frischer T, Meinert R, Urbanek R, Kuehr J. Variability of peak expiratory flow rate in children: short and long term reproducibility. Thorax 1995; 50: 35-39.
7. Bacharier LB, Strunk RC, Mauger D, White D, Lemanske Jr RF, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 2004; 170: 426-432. (Pubitemid 39214618)
8. Wildhaber JH, Sznitman J, Harpes P, Straub D, Moller A, Basek P et al. Correlation of spirometry and symptom scores in childhood asthma and the usefulness of curvature assessment in expiratory flow-volume curves. Respir Care 2007; 52: 1744-1752.
9. Horak E, Grassl G, Skladal D, Ulmer H. Lung function and symptom perception in children with asthma and their parents. Pediatr Pulmonol 2003; 35: 23-28. (Pubitemid 36009009)
10. Kainu A, Lindqvist A, Sarna S, Lundback B, Sovijarvi A. FEV1 response to bronchodilation in an adult urban population. Chest 2008; 134: 387-393.
11. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130: 487-495. (Pubitemid 29135801)
12. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13: 1353-1359. (Pubitemid 38961642)
13. EPR-3 Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma (EPR-3 2007) NIH Publication No. 08-4051. Bethesda, MD: U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program, 2007.
14. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117: 18-24;quiz 25. (Pubitemid 43017132)
15. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JP. An empirical evaluation of multifarious outcomes in pharmacogenetics: beta-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenet Genomics 2006; 16: 705-711. (Pubitemid 44454864)
16. Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987; 84: 46-50. (Pubitemid 17013575)
17. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006; 174: 1101-1109. (Pubitemid 44772080)
18. Chu X, Dong Y, Shen M, Sun L, Dong C, Wang Y et al. Polymorphisms in the ADRB2 gene and Graves disease: a case-control study and a metaanalysis of available evidence. BMC Med Genet 2009; 10: 26.
19. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334-339.
20. Belfer I, Buzas B, Evans C, Hipp H, Phillips G, Taubman J et al. Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans. Eur J Hum Genet 2005; 13: 341-351. (Pubitemid 40360790)
21. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184-3188. (Pubitemid 28022857)
22. Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005; 171: 563-570. (Pubitemid 40365410)
23. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75-80. (Pubitemid 30469801)
24. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ et al. Use of regularly scheduled albuterol treatment in asthma: genotypestratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-1512. (Pubitemid 39410416)
25. Wechsler ME, Lehman E, Lazarus SC, Lemanske Jr RF, Boushey HA, Deykin A et al. Beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173: 519-526.
26. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118-2125. (Pubitemid 350296302)
27. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374: 1754-1764.
28. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181: 676-687.
29. Bleecker ER, Lawrance RM, Ambrose HJ, Goldman M. Beta2-adrenergic receptor gene polymorphisms: is Arg/Arg genotype associated with serious adverse events during treatment with budesonide and formoterol in one pressurized metered-dose inhaler (BUD/FM pMDI) within racial groups? Am J Respir Crit Care Med 2008; 177: A775.
30. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26. (Pubitemid 43265239)
31. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97: 10483-10488.
32. Que LG, Yang Z, Stamler JS, Lugogo NL, Kraft M. S-nitrosoglutathione reductase: an important regulator in human asthma. Am J Respir Crit Care Med 2009; 180: 226-231.
33. Choudhry S, Que LG, Yang Z, Liu L, Eng C, Kim SO et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics 2010; 20: 351-358.
34. Litonjua AA, Lasky-Su J, Schneiter K, Tantisira KG, Lazarus R, Klanderman B et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008; 178: 688-694.
35. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004; 84: 731-765. (Pubitemid 38823765)
36. Zimmermann N, King NE, Laporte J, Yang M, Mishra A, Pope SM et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003; 111: 1863-1874. (Pubitemid 38057731)
37. Vonk JM, Postma DS, Maarsingh H, Bruinenberg M, Koppelman GH, Meurs H. Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. Pharmacogenet Genomics 2010; 20: 179-186.
38. Duan QL, Gaume BR, Hawkins GA, Himes BE, Bleecker ER, Klanderman B et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med 2010; 183: 449-454.
39. Himes BE, Wu AC, Duan QL, Klanderman B, Litonjua AA, Tantisira K et al. Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics 2009; 10: 1393-1412.
40. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002; 15: 35-50. (Pubitemid 34971552)
41. Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham S et al. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression. Am Rev Respir Dis 1993; 148: 401-406. (Pubitemid 23221585)
42. Powell N, Till SJ, Kay AB, Corrigan CJ. The topical glucocorticoids beclomethasone dipropionate and fluticasone propionate inhibit human T-cell allergen-induced production of IL-5, IL-3 and GM-CSF mRNA and protein. Clin Exp Allergy 2001; 31: 69-76. (Pubitemid 32158763)
43. John M, Lim S, Seybold J, Jose P, Robichaud A, O'Connor B et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998; 157: 256-262. (Pubitemid 28071290)
44. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 1997; 155: 845-851. (Pubitemid 27133392)
45. Cooper PR, Panettieri Jr RA. Steroids completely reverse albuterolinduced beta(2)-adrenergic receptor tolerance in human small airways. J Allergy Clin Immunol 2008; 122: 734-740.
46. Nino G, Hu A, Grunstein JS, Grunstein MM. Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure. J Allergy Clin Immunol 2010; 125: 1020-1027.
47. Jin SL, Goya S, Nakae S, Wang D, Bruss M, Hou C et al. Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2010; 126: 1252-1259, e1212.
48. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109: 410-418. (Pubitemid 34234189)
49. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998; 139: 403-413. (Pubitemid 28166335)
50. Silverman ES, Breault DT, Vallone J, Subramanian S, Yilmaz AD, Mathew S et al. Corticotropin-releasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma. J Allergy Clin Immunol 2004; 114: 747-754. (Pubitemid 39330242)
51. Dijkstra A, Koppelman GH, Vonk JM, Bruinenberg M, Schouten JP, Postma DS. Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. J Allergy Clin Immunol 2008; 121: 1510-1513. (Pubitemid 351787354)
52. Tantisira KG, Lazarus R, Litonjua AA, Klanderman B, Weiss ST. Chromosome 17: association of a large inversion polymorphism with corticosteroid response in asthma. Pharmacogenet Genomics 2008; 18: 733-737.
53. Hawkins GA, Lazarus R, Smith RS, Tantisira KG, Meyers DA, Peters SP et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol 2009; 123: 1376-1383, e1377.
54. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655-669.
55. Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002; 295: 336-338. (Pubitemid 34074365)
56. Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA 2004; 101: 18099-18104. (Pubitemid 40054080)
57. Raby BA, Hwang ES, Van Steen K, Tantisira K, Peng S, Litonjua A et al. T-bet polymorphisms are associated with asthma and airway hyperresponsiveness. Am J Respir Crit Care Med 2006; 173: 64-70. (Pubitemid 43069789)
58. Fischer A, Konig W. Regulation of CD23 expression, soluble CD23 release and immunoglobulin synthesis of peripheral blood lymphocytes by glucocorticoids. Immunology 1990; 71: 473-479.
59. Tantisira KG, Silverman ES, Mariani TJ, Xu J, Richter BG, Klanderman BJ et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007; 120: 1285-1291. (Pubitemid 350216603)
60. Jin Y, Hu D, Peterson EL, Eng C, Levin AM, Wells K et al. Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. J Allergy Clin Immunol 2010; 126: 618-625, e611-612.
61. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104: 15858-15863. (Pubitemid 350035389)
62. Hakonarson H, Bjornsdottir US, Halapi E, Bradfield J, Zink F, Mouy M et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci USA 2005; 102: 14789-14794. (Pubitemid 41457134)
63. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirinsensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148(6 Part 1): 1447-1451. (Pubitemid 24002469)
64. Reiss TF, Hill JB, Harman E, Zhang J, Tanaka WK, Bronsky E et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52: 1030-1035. (Pubitemid 27515780)
65. Scadding GW, Scadding GK. Recent advances in antileukotriene therapy. Curr Opin Allergy Clin Immunol 2010; 10: 370-376.
66. Ogawa Y, Calhoun WJ. The role of leukotrienes in airway inflammation. J Allergy Clin Immunol 2006; 118: 789-798; quiz 799-800. (Pubitemid 44498776)
67. Lima JJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther 2007; 11: 97-104. (Pubitemid 46572570)
68. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99: 1130-1137. (Pubitemid 27123651)
69. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22: 168-170. (Pubitemid 29264811)
70. Telleria JJ, Blanco-Quiros A, Varillas D, Armentia A, Fernandez-Carvajal I, Jesus Alonso M et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008; 102: 857-861.
71. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS, van den Oord EJ et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17: 189-196. (Pubitemid 46668003)
72. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173: 379-385. (Pubitemid 43228324)
73. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics 2009; 19: 244-247.
74. Brechot JM, Hurbain I, Fajac A, Daty N, Bernaudin JF. Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium. J Histochem Cytochem 1998; 46: 513-517. (Pubitemid 28158471)
75. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55(Suppl 2): S28-S31.
76. Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002; 32: 949-955. (Pubitemid 36002038)
77. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12: 565-570. (Pubitemid 35177087)
78. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19: 129-138.
79. Kim JH, Lee SY, Kim HB, Jin HS, Yu JH, Kim BJ et al. TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma. Clin Exp Allergy 2008; 38: 51-59.
80. Kang MJ, Kwon JW, Kim BJ, Yu J, Choi WA, Shin YJ et al. Polymorphisms of the PTGDR and LTC4S influence responsiveness to leukotriene receptor antagonists in Korean children with asthma. J Hum Genet 2011; 56: 284-289.
81. Kang MJ, Lee SY, Kim HB, Yu J, Kim BJ, Choi WA et al. Association of IL-13 polymorphisms with leukotriene receptor antagonist drug responsiveness in Korean children with exercise-induced bronchoconstriction. Pharmacogenet Genomics 2008; 18: 551-558.
82. Kabesch M, Michel S, Tost J. Epigenetic mechanisms and the relationship to childhood asthma. Eur Respir J 2010; 36: 950-961.
83. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002; 166: 392-396. (Pubitemid 34864433)
84. Walsh KM, Bracken MB, Murk WK, Hoh J, Dewan AT. Association between reduced copy-number at T-cell receptor gamma (TCRgamma) and childhood allergic asthma: a possible role for somatic mosaicism. Mutat Res 2010; 690: 89-94.
85. Meyer UA. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 669-676. (Pubitemid 39150124)